Heron Therapeutics, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024, on February 27, 2025. The company achieved GAAP net income of $3.663 million in Q4 2024, a significant milestone compared to a net loss of $10.724 million in Q4 2023. Full-year 2024 net product sales reached $144.285 million, an increase of 13.6% over 2023.
The acute care franchise demonstrated robust growth, with Q4 2024 net sales increasing by 68.5% to $10.389 million. APONVIE sales surged by 311.1%, and ZYNRELEF sales grew by 48.5% in the quarter. For the full year, acute care sales were up 57.3% to $30.064 million, driven by ZYNRELEF and APONVIE.
Heron provided full-year 2025 guidance, projecting net revenue between $153.0 million and $163.0 million, and adjusted EBITDA between $0.0 million and $8.0 million. CEO Craig Collard highlighted 2024 as a milestone year, emphasizing ZYNRELEF's readiness for transformational growth due to expanded label indications, the VAN launch, the NOPAIN Act approval, and the Crosslink relationship.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.